Invenio Imaging, Inc.

Invenio Imaging, Inc. develops and commercializes the NIO Laser Imaging System, a stimulated Raman histology (SRH) platform that enables rapid, label-free tissue imaging for intraoperative pathology assessment. The NIO system delivers high-quality histological images in under 3 minutes without requiring tissue staining or sectioning, allowing on-site evaluation by surgical and pathology staff. The platform features the NIO Slide sample preparation module and integrates natively with existing hospital IT infrastructure via DICOM interfaces for digital image sharing and archiving. Invenio Imaging also offers NIO Glioma Reveal, a deep learning–based image analysis algorithm for identifying cancer infiltration in glioma surgery; this product has received CE Mark approval in the European Union and is available for research use only in the United States. The company serves multiple surgical specialties including neurosurgery, interventional pulmonology, urology, ENT, breast oncology, GI endoscopy, organ transplantation, and nephrology. The technology preserves tissue viability for downstream molecular and genetic analysis, enabling pathologists to conduct additional studies on the same specimen. The NIO platform has exceeded 2,000 installed systems globally and is supported by clinical evidence from leading academic medical centers including NYU Langone Health and University of Freiburg.